Trevena Inc.

(TRVN) Trade

By |

Profile

Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain.

Contact Information

Website: www.trevenainc.com
Email: IR@trevenainc.com
Main Phone: +1 610 354-8840
Address: 955 Chesterbrook Boulevard
Address 2: Suite 200
State: PA
City / Town: Chesterbrook
Country: USA
Postal Code: 19087

Issuer Information

Exchange: NGS
CEO: Carrie L. Bourdow
Employees: 51
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 0.58 $ -0.0279 (-4.58%)
Last Price 0.58 Change $ -0.0279 Change % -4.58 Tick N/A
Bid 0.56 Bid Size 3,400.00 Ask 0.63 Ask Size 36,200.00
Open 0.62 High 0.63 Low 0.57 Prev Close 0.61
Last Trade Volume 1.5 mi 52 Wk Hi 3.58 52 Wk Low 0.55
Market Cap 47.8 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 82,323,413.00 EPS (TTM) -0.56 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 1 1
Number of Buys 0 0
Number of Sells 1 1
Net Activity -5000 -5000
Last 10 Buys Shares
Carrie L. Bourdow 1,000
Maxine Gowen 1,000
Yacoub Habib 1,000
Maxine Gowen 1,000
Maxine Gowen 1,000
Maxine Gowen 1,000
Roberto Cuca 1,000
John M. Limongelli 1,000
Last 10 Sell Shares
Yacoub Habib 1,000
Michael W. Lark 1,000
David Soergel 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 10 10 10 10
Low Target Price Estimate 2.5 2.5 2.5 2.5
Mean Target Price Estimate 6.92 6.92 6.92 6.92
Standard Deviation 2.91 2.91 2.91 2.91
Date of Most Recent Estimate 05/23/18 05/23/18 05/23/18 05/23/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 1 1
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.4 1.4 1.5 1.5